Novacyt S.A. (NYZ)

Overview

Novacyt S.A. is a distinguished entity in the global health sector, primarily specializing in the provision of in vitro and molecular diagnostic tests. Since its inception in 2006, the company has been pivotal in addressing a range of infectious diseases. With its headquarters located in Vélizy-Villacoublay, France, Novacyt has broadened its reach, catering to diverse markets including the United Kingdom, other parts of Europe, the United States, Asia Pacific, the Middle East, and Africa. The company’s operation is structured across three main segments: Primer Design, Lab21 Products, and IT-IS International. Each of these segments plays a unique role in Novacyt’s commitment to advancing medical diagnostics, contributing to its reputation as a leader in infectious disease testing.

Products and Services

• Primer Design

  This segment of Novacyt S.A. is dedicated to the design, manufacture, and marketing of molecular real-time qPCR testing devices and reagents. Primarily focusing on infectious diseases, products from this division are pivotal in the rapid and accurate detection of pathogens, thereby enabling timely and effective clinical interventions.

• Lab21 Products

  Under the Lab21 Products segment, Novacyt expands its diagnostic reach to protein-based infectious disease in-vitro diagnostic device (IVD) products. This line of products is developed, manufactured, and distributed by the company, showcasing its versatility in the production of diagnostic solutions by utilizing different technological bases and methodologies for disease detection.

• IT-IS International

  The IT-IS International segment stands out for its specialized focus on the development and manufacturing of PCR (Polymerase Chain Reaction) devices. These devices find their application not only in the life sciences arena but also in the food testing industry, illustrating the broad applicability of Novacyt's technological innovations beyond traditional medical diagnostics.